Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20874Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Schweigerer, L. | en |
| dc.contributor.author | Fotsis, T. | en |
| dc.date.accessioned | 2015-11-24T19:10:50Z | - |
| dc.date.available | 2015-11-24T19:10:50Z | - |
| dc.identifier.issn | 0300-8630 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20874 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Cell Division/physiology | en |
| dc.subject | Cell Line | en |
| dc.subject | Cell Transformation, Neoplastic/genetics | en |
| dc.subject | Child | en |
| dc.subject | Gene Expression Regulation, Neoplastic/physiology | en |
| dc.subject | Genes, myc/genetics | en |
| dc.subject | Humans | en |
| dc.subject | Mice | en |
| dc.subject | Mice, Nude | en |
| dc.subject | Neoplasm Transplantation | en |
| dc.subject | Proto-Oncogene Proteins c-myc/genetics | en |
| dc.subject | Transfection/genetics | en |
| dc.subject | Tumor Necrosis Factor-alpha/physiology | en |
| dc.title | Increased expression of the MYCN oncogene in human neuroblastoma cells and possible, new therapeutic approaches | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1055/s-2007-1025447 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/1942938 | - |
| heal.identifier.secondary | https://www.thieme-connect.de/DOI/DOI?10.1055/s-2007-1025447 | - |
| heal.language | de | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1991 | - |
| heal.abstract | Human neuroblastomas of advanced stages often display amplification with a consecutive enhanced expression of the MYCN oncogene. Enhanced MYCN expression is thought to contribute in a causative manner to the progression of neuroblastomas, but the mechanisms by which this may occur have remained unclear. By transfecting human neuroblastoma cells that display a normal MYCN expression with the human MYCN oncogene, we have generated a cell line with enhanced MYCN expression and thereby were able to compare the biological and biochemical properties of the transfected and non-transfected cells. We have demonstrated autocrine growth factors in the MYCN-transfected, but not the non-transfected, neuroblastoma cells. Identification of the primary structures of these factors may help to develop specific antagonists in order to improve the therapy of advanced neuroblastomas. Currently, this could be done by application of genistein or tumor necrosis factor. As we could demonstrate for the first time, the dietary constituent genistein is able to inhibit the proliferation of neuroblastoma cells with enhanced and normal MYCN expression, but also that of cells derived from other solid pediatric tumors. In contrast, tumor necrosis factor is able to inhibit selectively the proliferation of neuroblastoma cells with enhanced MYCN expression. We suggest that tumor necrosis factor might improve the therapy of advanced human neuroblastomas. | en |
| heal.journalName | Klin Padiatr | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
